Objective. Systemic sclerosis (SSc) is a major cause of pulmonary arterial hypertension (PAH). Murine models indicate key roles for chemokines CCL19 and CCL21 and their receptor CCR7 in lung inflammation leading to PAH. The objective of this study was to assess the chemokine CCL19-CCL21 axis in patients with SSc-related PAH.
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Objective. Systemic sclerosis (SSc) is a major cause of pulmonary arterial hypertension (PAH). Murine models indicate key roles for chemokines CCL19 and CCL21 and their receptor CCR7 in lung inflammation leading to PAH. The objective of this study was to assess the chemokine CCL19-CCL21 axis in patients with SSc-related PAH.
Methods. Serum samples obtained from 2 independent prospective SSc cohorts (n = 326), patients with idiopathic PAH (n = 12), and healthy control subjects (n = 100) were analyzed for CCL19/CCL21 levels, by enzyme-linked immunosorbent assay. The levels were defined as either high or low, using the mean + 2 SD value in controls as the cutoff value. Risk stratification at the time of PAH diagnosis and PAH-related events were performed. Descriptive and Cox regression analyses were conducted.
Results. CCL21 levels were higher in patients with SSc compared with controls and were elevated prior to the diagnosis of PAH. PAH was more frequent in patients with high CCL21 levels (≥0.4 ng/ml) than in those with low CCL21 levels (33.3% versus 5.3% [P < 0.001]). In multivariate analyses, CCL21 was associated with PAH (hazard ratio [HR] 5.1, 95% CI 2.39-10.76 [P < 0.001]) and occurrence of PAH-related events (HR 4.7, 95% CI 2.12-10.46, P < 0.001). Risk stratification at the time of PAH diagnosis alone did not predict PAH-related events. However, when risk at diagnosis was combined with high or low CCL21 level, there was a significant predictive effect (HR 1.3, 95% CI 1.03-1.60 [P = 0.027]). A high CCL21 level was associated with decreased survival (P < 0.001).
Conclusion. CCL21 appears to be a promising marker for predicting the risk of SSc-related PAH and PAH progression. CCL21 may be part of a dysregulated immune pathway linked to the development of lung vascular damage in SSc.
Systemic sclerosis (SSc) is a complex autoimmune disorder characterized by progressive fibrosis of the skin and internal organs, vascular pathology, and distinct autoantibodies in serum (1) . Mortality is high, and precapillary pulmonary hypertension (PH) and interstitial lung disease (ILD) are major causes (2) (3) (4) . The 2 main forms of PH in SSc are pulmonary arterial hypertension (PAH) (World Health Organization [WHO] group 1) and PH secondary to ILD (WHO group 3 PH). It is important to differentiate these forms, because SSc-related PAH may respond to targeted PH therapies, particularly if treatment is introduced at an early stage when vascular damage is not too advanced, while SSc-related PH complicating ILD (PH-ILD) is resistant to current therapies (5) (6) (7) (8) .
Unfortunately, the onset of PH in patients with SSc is typically insidious, resulting in delayed diagnosis (9) . Multimodal screening by echocardiography, N-terminal pro-brain natriuretic peptide (NT-proBNP) tests, and pulmonary function tests (PFTs) may reduce diagnostic delay (10) (11) (12) , but this is an expensive strategy that primarily detects established PH and does not differentiate PAH from PH-ILD. Hence, there is an unmet need for early and specific PAH (WHO group 1) markers in SSc for early diagnosis.
Immune processes originating in the lungs appear to drive the development of PAH (13) , and various studies indicate that these immune processes may leave distinct fingerprints in the systemic circulation (14) (15) (16) (17) . A prime example is the high systemic level of chemokine CXCL4 that was recently identified in SSc-related PAH (16) . Surprisingly, the CXCL4 level was also elevated in patients in whom ILD was developing, indicating low specificity for PAH (16) . The effects of age were not assessed in the CXCL4 study. This was unfortunate, because age is a risk factor for SSc-related PAH (18, 19) and appears to influence systemic chemokine levels (20, 21) .
Data derived from murine models support the notion of PAH as an immune-driven process and have identified chemokine receptor CCR7 and its ligands CCL19 and CCL21 as potential factors in PAH development (22) . This chemokine axis is essential for directing naive T cells to dendritic cells in lymph nodes but is also highly inducible in the periphery, with selective induction of CCL21 in lung tissue (23) . Mice deficient in CCR7 have perivascular lung inflammation and develop PAH (24) , and there are indications of dysregulated CCR7 and/or CCL21 in human PAH (25, 26) . These observations are consistent with the notion that CCL21 is a potent regulator of angiogenesis (27) and a marker of vascular inflammation and damage in human cardiovascular diseases (28, 29) .
We hypothesized that the CCR7-CCL19/CCL21 axis could be dysregulated in SSc-related PAH. To approach this issue, we analyzed serum samples from a large, prospective, well-characterized SSc cohort covering the whole spectrum of disease severities, including complete longitudinal data sets on PAH and ILD (30) (31) (32) . Follow-up analyses were performed in patients with idiopathic PAH, and the data were validated in an independent cohort of patients with SSc-related PAH (33) .
PATIENTS AND METHODS
Study cohorts. All included SSc patients from the unselected, prospective Oslo University Hospital SSc cohort met the American College of Rheumatology/European League Against Rheumatism 2013 classification criteria for SSc (31) and had serum samples and complete longitudinal data on cardiopulmonary disease development available (as detailed below) (30) . As internal controls, we included serum samples from 12 patients with idiopathic PAH at the Department of Cardiology, Oslo University Hospital and from 100 healthy blood donors. All serum samples were collected in Nunc tubes (Thermo Fisher), processed within 30 minutes, and stored according to the Oslo University Hospital protocol. For validation, we selected SSc patients with and those without PAH from the prospective Lund University Hospital SSc cohort. All patients selected from the Lund cohort met the inclusion criteria described above. The study was conducted in compliance with (34) . Disease onset was defined as the first non-Raynaud's phenomenon manifestation of SSc, and disease duration was defined as the period from disease onset until study end (June 2017) or time of death.
Serial assessments of ILD. Paired PFTs and highresolution computed tomography (HRCT) lung images from baseline and the last available follow-up visit were analyzed as previously described (30, 32, 35) . Briefly, the extent of lung fibrosis was expressed as the percentage of total lung volume, and PFTs were carried out according to the American Thoracic Society/European Respiratory Society guidelines, using an automated Vmax V6200 system (SensorMedics) (30, 36) .
PH surveillance, diagnostic procedures, and PAH risk stratification at diagnosis. Annual PH surveillance procedures in the Oslo and Lund SSc cohorts include complete clinical examination, echocardiography with estimated systolic pulmonary artery pressure (PAP), PFTs, 6-minute walk test, and NTproBNP test. These data were retrieved for the baseline visit and the last available assessment (follow-up). The threshold for referral for right-sided heart catheterization (RHC) is low, and the indication is based on clinical suspicion of PH, typically due to increasing or unexplained dyspnea, a significant decline in the diffusing capacity for carbon monoxide (DLCO), increasing NTproBNP levels, and a systolic blood pressure of >40 mm Hg as determined by echocardiography. In January 2014, the DETECT algorithm was added to the Oslo University Hospital SSc protocol, and all patients with a DETECT score of >35 were referred for RHC (37) .
PH was diagnosed by RHC according to the European Society of Cardiology (ESC) guidelines, using a Swan-Ganz pulmonary artery thermodilution catheter (Baxter Healthcare) (38, 39) . A follow-up RHC was conducted if it was clinically indicated. Differentiation between SSc-related PAH (WHO group 1) and PH-ILD (WHO group 3) was performed as previously described (11) , with SSc-related PAH defined as the presence of precapillary PH and the absence of significant lung fibrosis (<10% on HRCT) and forced vital capacity (FVC) of >70% of the predicted value at both baseline and follow-up, with other causes of precapillary PH ruled out (6) . Risk stratification at the time of PAH diagnosis was performed using the low-risk, intermediaterisk, and high-risk grouping system suggested in the 2015 ESC guidelines (38) . Patients with ≥1 measure of poor prognosis were considered to be at high risk, and those with ≥1 measure of intermediate prognosis were considered to be at intermediate risk. The composite outcome measure "PAH-related events" was defined as previously described (40) and included PAH progression, end-stage PAH, hospitalization for PAH worsening, and all-cause mortality.
Chemokine enzyme-linked immunosorbent assay. Blood samples from all patient populations (SSc, idiopathic PAH, and controls) at Oslo University Hospital and Lund University Hospital were obtained according to the same standardized procedures, and processing and storing of blood samples were similar in these cohorts. The European League Against Rheumatism (EULAR)/EULAR Scleroderma Trial and Research recommendations for biobanking (41) were followed. Samples were centrifuged at room temperature within 30 minutes, and serum aliquots were stored at À70°C until assayed. Circulating CCL19 and CCL21 were analyzed in all samples by enzyme immunoassay (R&D Systems) using undiluted serum in all included samples at Oslo University Hospital, and all samples were measured in duplicate. The 100 healthy control samples were drawn from blood bank donors. The Norwegian law for blood donors is strict, allowing inclusion of only healthy individuals without cardiovascular disease, immune deficiencies, any chronic disease, or infection.
Statistical analysis. Analyses were performed using IBM SPSS software version 22 and Stata version 14. Pearson's chi-square test, Fisher's exact test, or t-test for independent samples was used as appropriate. For correlation analyses, Pearson's or Kendall's tau-b coefficients were applied as appropriate, and Cohen's criteria for correlation were applied (<0.3 = medium correlation, and <0.5 = strong correlation). Cox regression analyses with hazard ratios (HRs) and 95% confidence intervals (95% CIs) were applied to analyze cardiopulmonary outcome measures. The association, predictive value, and the prognostication of CCL21 in relation to PAH were evaluated by Cox regression analyses. Independent risk factors from univariable analyses with a significance level of 20%, along with all variables of known clinical importance were included in the multivariable Cox regression analysis. A manual backward stepwise elimination procedure was performed to identify independent risk factors for PAH (42) . Multivariable analyses were preceded by an estimation of the correlation between risk factors. To avoid multicollinearity between age at onset and CCL21 levels, separate models including either CCL21 (model 1) or age at onset (model 2) were constructed and discriminated by the C index (values >0.7 were considered acceptable). Cumulative survival rates were computed using the Kaplan-Meier method, and significance was determined by log rank test. Items with significant effects on survival were entered into the Cox proportional hazards model.
RESULTS
Serum levels of CCL21 in the SSc cohort and controls. In total, 298 SSc patients from the prospective Oslo University Hospital SSc cohort were included (Figure 1 ). Demographics and clinical characteristics of the subjects are shown in Table 1 . The serum levels of CCL19 did not differ between the groups (Figure 2A ). The mean AE SD CCL21 levels in serum were higher in SSc patients (0.36 Figure 1 . Flow chart of the included patients from the Oslo University Hospital and Lund University Hospital cohorts. Inclusion of all subjects from the Oslo and Lund cohorts, the number of right-sided heart catheterizations (RHCs) conducted, and the frequency of pulmonary hypertension (PH), categorized according to World Health Organization (WHO) groups for PH, are shown. All included subjects had sera analyzed for CCL21 (red bar) and all patients had available clinical data (yellow bar). Systemic sclerosis (SSc) patients with pulmonary arterial hypertension (PAH) (dark pink-shaded box) were included in the association studies. Light pink-shaded box indicates predictive studies, and blue-shaded boxes indicate prognotication studies. Echo = echocardiography; NT-proBNP = N-terminal pro-brain natriuretic peptide; PFT = pulmonary function test; HRCT = high-resolution computed tomography; iPAH = idiopathic PAH. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40534/abstract. AE 0.24 ng/ml) compared with those in 100 healthy controls (0.18 AE 0.06 ng/ml [P < 0.001]) ( Figure 2B ). CCL21 levels did not differ between patients with limited cutaneous SSc and patients with diffuse cutaneous SSc ( Figure 2C ), across major SSc-related autoantibodies ( Figure 2D ), or in patient with and those without SScrelated ILD. In the Oslo cohort, the highest CCL21 levels were in SSc patients with PAH (n = 41) followed by patients with PH secondary to ILD (n = 25) ( Figure 2E and Table 1 ). The CCL19 level was not elevated in patients with PAH. The finding of elevated CCL21 levels in patients with SSc-related PAH was confirmed in an independent cohort from Lund University Hospital (n = 28). CCL21 levels were similar in PAH patients from the Oslo (n = 41) and Lund cohorts (n = 16) ( Table 1) . Additionally, elevated CCL21 levels were not observed in the limited number of patients with idiopathic PAH (n = 12) ( Figure 2E) .
A CCL21 level of ≥0.40 ng/ml (i.e., more than +2 SD of the mean level in healthy controls) was identified in 90 of 298 SSc patients in the Oslo cohort. These 90 patients were defined as the "CCL21 high" subset, while the remaining 208 patients with a CCL21 level of <0.40 ng/ml were defined as the "CCL21 low" subset. Patients in these 2 subsets were similar with regard to disease duration but differed in age at disease onset and sex distribution. We did not observe that use of immunosuppressive drugs had any impact on the CCL21 analyses.
Absolute risk of cardiopulmonary disease in the CCL21 high and CCL21 low subsets of SSc patients. Among the 298 SSc patients from the Oslo cohort, 126 (43.3%) underwent at least 1 RHC during the observation period and was diagnostic for PAH in 41 SSc patients with WHO group 1 (PAH) and 25 with WHO group 3 (PH-ILD) (Figure 1 ). Patients with WHO groups 2, 4, and 5 (n = 13) were excluded from further analyses. In the CCL21 high subset, we estimated the absolute risk of developing PAH during the observation period to be 33.3% (30 of 90 patients), while it was 5.3% (11 of 208 patients) in the CCL21 low subset. Hence, as a stand-alone PAH test item in this unselected SSc cohort, serum CCL21 showed 80% specificity and 73% sensitivity.
Analyses of RHC parameters indicated more severe PAH in the CCL21 high subset (Table 2) , and further analyses showed that the CCL21 level correlated with the cardiac index (r = À0.28, P = 0.019), pulmonary vascular resistance (r = 0.5, P = 0.004), and SvO 2 (r = À0.34, P = 0.045). Consistent with the RHC data, we observed higher baseline estimated systolic PAP and plasma NT-proBNP levels in the CCL21 high subset (Table 2) . Moreover, the CCL21 high subset had lower DLCO values at baseline compared with the low CCL21 subset (mean AE SD 62.6 AE 22.9 versus 70.6 AE 20.8; P = 0.004) and an increased frequency of a decrease in the DLCO of >15% per year (50 AE 25.5% versus 35 AE 39.8%; P = 0.015). CCL21 was also correlated with the C-reactive protein (CRP) level (r = 0.4, P < 0.001) and the erythrocyte sedimentation rate (ESR) (r = 0.4, P < 0.001). Parameters associated with SSc-related ILD (baseline FVC, annual FVC deterioration, baseline extent of lung fibrosis, and annual progression of lung fibrosis) did not differ between the CCL21 high and CCL21 low subsets. The mean AE SD time from disease onset to PAH diagnosis was shorter in the CCL21 
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Associations between CCL21 and PAH in SSc. For these analyses, we included all patients in the Oslo and Lund cohorts who had undergone an RHC procedure. In 57 patients (41 from the Oslo cohort and 16 from the Lund cohort), PAH was diagnosed during the observation period ( Figure 1 ). Univariable Cox regression analyses showed that CCL21 was associated with PAH (HR 3.3, 95% CI 1.81-5.97 [P < 0.001]) and age at onset (HR 1.12, 95% CI 1.08-1.15 [P < 0.001]). There was a significant correlation between CCL21 and age at onset (r = 0.4, P < 0.001), and 2 separate multivariable models were chosen to avoid multicollinearity (1 including CCL21 and 1 including age). C-index analyses of the 2 models showed superiority of the model that included CCL21 (model 1) compared with the model including age at onset (model 2) (C index 0.89 and 0.84, respectively). In the superior multivariable model, we observed that CCL21, anticentromere antibodies (ACAs), systolic PAP by echocardiography, and DLCO were independently associated with PAH (Table 3) .
CCL21 and prediction of PAH development in the SSc cohort. To estimate the predictive value of CCL21 for development of PAH, we analyzed data for patients in whom the serum samples used for CCL21 analyses had Figure 2 . A and B, CCL19 levels (A) and CCL21 levels (B) in healthy control subjects and patients with SSc from the Oslo University Hospital cohort. Horizontal lines show the mean. C, CCL21 levels in SSc patients categorized as having diffuse cutaneous SSc or limited cutaneous SSc. D, CCL21 levels stratified by positivity for anticentromere (anti-CENP), anti-topoisomerase I (anti-topo I), and anti-RNAP III (anti-RNAP) antibodies. E, CCL21 levels in healthy control subjects, patients with SSc, patients with SSc-related PAH (SSc-PAH), patients with PH-related interstitial lung disease (PH-ILD), and patients with iPAH. In C-E, data are presented as box plots, where the boxes represent the 25th to 75th percentiles, the lines within the boxes represent the median, and the lines outside the boxes represent the 10th and 90th percentiles. The circle represents an outlier. See Figure 1 for other definitions.
been obtained >6 months prior to RHC, before PAH was diagnosed in the patients. Such pre-PAH samples were available for 40 patients (Figure 1) . The clinical characteristics of the 40 patients with pre-PAH samples did not differ from those of the 17 other Oslo/Lund cohort patients with SSc-related PAH. Again, due to strong collinearity between CCL21 and age at onset, we used 2 models to avoid multicollinearity and found that the model that included CCL21 (model 1) was superior to model 2 (C index 0.89 and 0.82, respectively). Using this model, we showed that factors independently predicting PAH were CCL21, ACAs, systolic PAP, and DLCO (Table 3) .
Utility of CCL21 for predicting PAH in patients with SSc. The value of CCL21 for predicting PAH-related events was assessed in the 41 patients with SSc-related PAH from the Oslo University Hospital cohort. At the time of PAH diagnosis, 12 of these 41 patients (29%) belonged to the low-risk subgroup, as defined by the 2015 ESC guidelines, while 32% had an intermediate risk and 39% had a high risk. CCL21 levels were significantly higher in the high-risk group compared with the intermediate-and low-risk subgroups (P < 0.001). During the observation period, 28 (68%) of 41 patients developed a PAH-related composite event. In univariable analyses, baseline variables associated with the development of a PAH event were CCL21 (HR 4.7, 95% CI 2.12-10. 46 * Except where indicated otherwise, values are the mean AE SD. SSc = systemic sclerosis; PAH = pulmonary arterial hypertension; mPAP = mean pulmonary artery pressure; PVR = pulmonary vascular resistance; NTproBNP = N-terminal pro-brain natriuretic peptide. † Low CCL21 versus high CCL21. ‡ Measured in 25 patients in the low CCL21 subset and 16 patients in the high CCL21 subset. * Adjusted multivariable Cox regression analyses included all patients with systemic sclerosis in the Oslo University Hospital and Lund University Hospital cohorts who had pulmonary arterial hypertension (PAH) diagnosed by right-sided heart catheterization and for whom data on CCL21 were available (n = 57). The model used for the prediction of PAH development included 40 patients in whom the serum samples used for the CCL21 analysis had been obtained >6 months before the diagnosis of PAH (i.e., pre-PAH serum samples). HR = hazard ratio; 95% CI = 95% confidence interval; ACAs = anticentromere antibodies; PAP = pulmonary artery pressure (by echocardiography); DLCO = diffusing capacity for carbon monoxide.
CCL21 AND PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS
resulting in 6 risk groups, the predictive value was significant (HR 1.3, 95% CI 1.03-1.60 [P = 0.027]). Follow-up RHC was performed in 26 (63.4%) of 41 patients. Analyses of serial RHC demonstrated that an increase in the mean pulmonary artery pressure from diagnosis to follow-up differed between the CCL21 high and CCL21 low subsets (9.1 mm Hg versus 1.6 mm Hg; P = 0.031). PAH treatment did not differ between the CCL21 high and CCL21 low subsets (data not shown).
Longitudinal assessment of CCL21 in the Oslo and Lund cohorts. At least 2 serum samples obtained at different time points (>12 months apart) were available for 126 (38.7%) of 326 SSc patients from the combined (Oslo and Lund) cohort. Analyses of these paired samples showed that the serum levels of CCL21 were stable across time in the vast majority of patients ( Figure 3A) . The cohort of 126 SSc patients with available serial serum samples included 20 patients in whom the first serum sample had been drawn at a time point before PAH was diagnosed by RHC (pre-PAH sample), while the last sample was drawn after PAH was diagnosed (post-PAH sample) ( Figure 3B ). Combined analyses of these pre-PAH and post-PAH samples showed that the level of CCL21 was elevated prior to PAH diagnosis and remained stably elevated over time, even after initiation of PAH treatment ( Figure 3B ).
High CCL21 level and survival in SSc. Eightyseven (29%) of 298 patients in the Oslo University Hospital SSc cohort and 16 (57%) of 28 patients in the Lund University Hospital SSc cohort died during the observation period; no causes of deaths were available. Patients with high CCL21 levels had reduced 5-year and 10-year cumulative survival compared with patients with low CCL21 levels (87% and 71% versus 96% and 91%, respectively [P < 0.001 by log rank test]). CCL21 (HR 2.1, 95% CI 1.21-3.70 [P = 0.008]) and age at onset (HR 1.1 95% CI 1.07-1.11 [P < 0.001]) were associated with mortality in univariate Cox proportional hazard analyses of the combined cohorts. We found that the model that included age (model 2) was superior to the model that included CCL21 (model 1) (C index 0.84 and 0.88, respectively).
DISCUSSION
There is an unmet need for biomarkers that allow for earlier detection of precapillary PH in patients with SSc. Here, we present data indicating the potential of CCL21 as a serum marker associated with early precapillary PH, with the strongest association with PAH, the predictive value for development of PAH, and progression of PAH. This observation may have implications for clinical practice, and it should contribute to new hypotheses about the immune mechanisms operative in SScassociated cardiopulmonary involvement that certainly could include CCL21-CCR7 interactions.
From a clinical point of view, we believe that the observed ability of CCL21 to predict PAH development is of key importance. The results of the current study suggest that a high CCL21 level in patients with SSc is specific for PAH and could be integrated with other known risk factors such as age, sex, the FVC:DLCO ratio, and ACA status in an improved algorithm for earlier detection and diagnosis of PAH (9, 18) . The serial sample analyses showed that serum levels of CCL21 were elevated prior to the diagnosis of PAH, indicating that the CCL21 level may be useful as a marker used to predict the development of PAH, but validation studies in independent cohorts, and prospective studies in unselected patient cohorts, with repeat serum samplings from disease onset and onward, are required to fully elucidate its predictive value in SSc. Additionally, our findings indicate that the CCL21 level may be helpful in risk stratification at the time of PAH diagnosis, thereby aiding decisions regarding treatment.
Earlier studies of SSc-related PH, including DETECT, focused on PH markers, such as echocardiographic right-sided heart strain measures and NTproBNP (10, 11) . Those studies provided valuable information but were designed to detect established PH and did not differentiate between the 2 major subtypes of SSc-related PH. Because of these limitations, there is an ongoing search for new markers linked to the pathogenesis of SSc-related PH. With the critical role of immune genes in SSc (44) , and the body of evidence linking aberrant immune activation to PH development (14) , the focus has been on markers with established or presumed immunologic functions. In 2014, van Bon et al reported that the CXCL4 level in plasma was highly elevated in patients with early diffuse cutaneous SSc and predicted the development of SSc-associated ILD and PAH (16) . This report of an association with both ILD and PAH contrasts with the findings in the current study, in which we concluded, based on complete longitudinal data sets (i.e., paired PFTs and lung HRCTs) that CCL21 was not associated with ILD. Thus, it is likely that CXCL4 and CCL21 mark different immune pathways related to SSc-related PAH. Because most studies of potential SSc-related PAH markers have not included ILD analyses, we do not know whether the CCL21 level is unique as a selective PAH marker (15, 17, 45, 46) . Interestingly, we observed that CCL21 levels were lower in patients with idiopathic PAH compared with those in patients with SSc-related PAH, indirectly supporting the notion that the mechanisms behind these PAH forms may differ (47) . These data should, however, be cautiously interpreted, because the number of cases of idiopathic PAH was low. Moreover, the patients with idiopathic PAH were younger than the patients with SSc-related PAH.
Due to the links between CCR7-CCL21 and vascular inflammation, it is tempting to speculate that CCL21 could mark pathways linked to angiogenesis, inflammation, and vascular damage. This notion is supported by the staining pattern of SSc-related PAH we observed (data not shown), which indicated that CCL21, expressed on endothelial cells, could recruit CCR7-positive mononuclear cells to the vascular wall and induce inflammation. This concept was also supported by the fact that CCL21 was correlated with the CRP level and the ESR, both of which are mononuclear cell markers.
In contrast to other immune-mediated systemic diseases, SSc is more severe in patients with an older age at disease onset (1). This is also true for SSc-related PAH, in which older age at onset is a negative prognostic factor (9). In the current study, we observed an agedependent increase in CCL21 levels in both patients with SSc and controls. Studies of age-associated immune dysregulation indicated that this age effect was physiologic (20, 21, 48) , but because it occurred in a setting in which there was a clear impact of age, we needed expert statistical advice to handle it correctly. The favored solution was to apply separate models for CCL21 and age at onset (see Patients and Methods).
We observed that high CCL21 levels were associated with reduced survival but appeared to have less influence on mortality compared with age at onset. This minor impact of CCL21 on mortality probably reflects that PAH, even though it is an important mortality risk factor, accounts for only 12% of all SSc deaths in Norway (3).
The current study has major strengths. First, it was performed in a large SSc cohort with complete longitudinal data sets for ILD and PH/PAH, and serial serum samples were available for one-third of the patients. Second, the study included control populations and a replication cohort with comparable SSc characteristics. Third, due to the unique personal identification numbers in Norway and the official mortality statistics, we had no "loss to followup." The most important limitations were interindividual variations in disease duration and observational length, which were attributable to the cohort study design in which patients are included consecutively and then followed up annually. Also, the controls and SSc patients were not completely matched for age and sex. This may have had a minor effect on the cutoff value used to define the high CCL21 and low CCL21 subsets but had no impact on the data regarding PAH. Finally, the blood samples from the Oslo and Lund cohorts were obtained at 2 different sites, which could possibly influence the chemokine levels.
In conclusion, our results indicate that CCL21 has promise for predicting the risk of pulmonary vascular disease associated with SSc. The data also indicate that CCL21 may be part of a dysregulated immune pathway that is operative in SSc and may be linked to the development of lung vascular damage. Further clinical and mechanistic studies are warranted to elucidate the roles of the CCR7-CCL21 axis in SSc.
